comparemela.com

Latest Breaking News On - Mobile android - Page 14 : comparemela.com

PPIs linked to risk for severe infection, decompensation in patients with cirrhosis

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress. “The safety of PPIs in cirrhosis remains quite controversial,” Nadim Mahmud, MD, MS, MPH, MSCE, assistant professor of medicine and

Joseph discusses AHA statement on managing CV risk in type 2 diabetes care

PHILADELPHIA — In this Healio video exclusive, Joshua J. Joseph, MD, MPH, FAHA, discussed the recent American Heart Association scientific statement on health equity in managing CV risk in type 2 diabetes.As Healio previously reported, the scientific statement, published in Circulation, is based on an extensive review of clinical trial results through June 2020 and addresses the managing of

FDA expands Breyanzi approval for relapsed or refractory large B-cell lymphoma

The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.

Molecular signature-assisted drug selection may improve results in rheumatoid arthritis

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy. “This study reports the second interim analysis of the [Accelerate Information of Molecular Signatures (AIMS)] real-world study evaluating the clinical utility of

FDA grants fast track designation to PDS0101 for head and neck cancer subset

The FDA granted fast track designation to PDS0101 for treatment of certain patients with head and neck cancer.The designation applies to use of the agent in combination with pembrolizumab (Keytruda, Merck) by patients with recurrent or metastatic HPV16-positive disease.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.